Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2016
Published Jul 20, 2016
133 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2016, provides in depth analysis on Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas

  
Source:
Document ID
GMDHC0399TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Overview91
Therapeutics Development105
  Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Products under Development by Stage of Development101
  Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Products under Development by Therapy Area111
  Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Products under Development by Indication123
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Pipeline Products Glance152
  Late Stage Products151
  Early Stage Products161
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Products under Development by Companies177
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Therapeutics Assessment245
  Assessment by Monotherapy/Combination Products241
  Assessment by Mechanism of Action251
  Assessment by Route of Administration262
  Assessment by Molecule Type281
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Companies Involved in Therapeutics Development2919
  AbbVie Inc.291
  Aclaris Therapeutics, Inc.301
  Advinus Therapeutics Ltd311
  Astellas Pharma Inc.321
  AstraZeneca Plc331
  Chipscreen Biosciences Ltd341
  CJ HealthCare Corp.351
  Concert Pharmaceuticals, Inc.361
  Eli Lilly and Company371
  Galapagos NV381
  Gilead Sciences, Inc.391
  Incyte Corporation402
  Nissan Chemical Industries, Ltd.421
  Pfizer Inc.431
  Portola Pharmaceuticals, Inc.441
  Sareum Holdings Plc451
  Theravance Biopharma, Inc.461
  Vectura Group Plc471
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Drug Profiles4865
  (INCB-039110 + INCB-040093) Drug Profile481
  ATI-50001 Drug Profile491
  ATI-50002 Drug Profile501
  AZD-0449 Drug Profile511
  AZD-1480 Drug Profile522
  AZD-4205 Drug Profile541
  baricitinib Drug Profile557
  cerdulatinib Drug Profile624
  CS-944X Drug Profile661
  CTP-543 Drug Profile671
  filgotinib Drug Profile689
  INCB-52793 Drug Profile771
  itacitinib adipate Drug Profile783
  momelotinib dihydrochloride Drug Profile815
  NIP-565 Drug Profile861
  peficitinib hydrobromide Drug Profile872
  PF-04965842 Drug Profile891
  PNQ-401 Drug Profile901
  PNQ-701 Drug Profile911
  ruxolitinib phosphate Drug Profile9213
  SAR-20347 Drug Profile1052
  Small Molecules to Inhibit Jak1 for Undisclosed Indication Drug Profile1071
  Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis Drug Profile1081
  TD-1473 Drug Profile1091
  upadacitinib tartrate Drug Profile1102
  VR-588 Drug Profile1121
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Dormant Projects1132
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Discontinued Products1152
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Featured News &Press Releases11715
  Jun 23, 2016: FDA Grants Breakthrough Therapy Designation for Incyte s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD)1171
  Jun 10, 2016: New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera1171
  Jun 09, 2016: Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs1181
  Jun 09, 2016: Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)1192
  Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor1211
  Jun 07, 2016: Results Of Clinical And Patient-Reported Outcomes Data For Baricitinib In Patients With Rheumatoid Arthritis To Be Presented At Annual European Congress Of Rheumatology1221
  Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis1231
  Jun 02, 2016: AbbVie To present Data on ABT-494 at the Annual European Congress of Rheumatology1241
  Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings1251
  May 25, 2016: FITZROY Phase 2 study with filgotinib in Crohns Disease presented as late breaker at DDW 20161261
  May 24, 2016: Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA)1261
  May 19, 2016: Incyte Highlights Jakafi (ruxolitinib) Abstract to be Presented at the 2016 ASCO and EHA Annual Meetings1271
  May 19, 2016: Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata1281
  May 04, 2016: Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata1291
  May 03, 2016: Parkinson's disease pathogenesis reduced in rat model by a cell-signaling inhibitor drug1293
Appendix1322
  Methodology1321
  Coverage1321
  Secondary Research1321
  Primary Research1321
  Expert Panel Validation1321
  Contact Us1321
  Disclaimer1331

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-JAK1-Janus-Kinase-1-or-JAK1-or-EC-2-7-10-2-Pipeline-Review-H2-2016-2088-16281>
  
APA:
Global Markets Direct - Market Research. (2016). Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-JAK1-Janus-Kinase-1-or-JAK1-or-EC-2-7-10-2-Pipeline-Review-H2-2016-2088-16281>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.